Pheochromocytoma classification: Difference between revisions
Jump to navigation
Jump to search
Ifrah Fatima (talk | contribs) |
Ifrah Fatima (talk | contribs) |
||
| (16 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
Pheochromocytomas and paragangliomas (collectively referred to as PPGLs) are rare [[tumors]] that originate from [[chromaffin cells]] in the [[adrenal medulla]] (pheochromocytoma) or in the extra-adrenal [[Ganglion|neural ganglia]] ([[paraganglioma]]). These [[tumors]] can be either biochemically active (producing a [[catecholamine]] like [[epinephrine]], [[Norepinephrine|nor-epinephrine]] and [[dopamine]]) or biochemically silent. PPGLs can be either sporadic or genetic, with association to several familial syndromes. PPGLs can also be classified according to their spread into local, regional, or [[Metastasis|metastatic.]] The defining characteristic of [[malignancy]] in PPGLs is the presence of [[metastasis]]. | Pheochromocytomas and paragangliomas (collectively referred to as PPGLs) are rare [[tumors]] that originate from [[chromaffin cells]] in the [[adrenal medulla]] (pheochromocytoma) or in the extra-adrenal [[Ganglion|neural ganglia]] ([[paraganglioma]]). These [[tumors]] can be either biochemically active (producing a [[catecholamine]] like [[epinephrine]], [[Norepinephrine|nor-epinephrine]] and [[dopamine]]) or biochemically silent. PPGLs can be either sporadic or genetic, with association to several familial syndromes. PPGLs can also be classified according to their spread into local, regional, or [[Metastasis|metastatic.]] The defining characteristic of [[malignancy]] in PPGLs is the presence of [[metastasis]]. | ||
==Classification== | ==Classification== | ||
Pheochromocytoma may be classified into several subtypes based on: | |||
Pheochromocytoma and paragangliomas may be classified into several subtypes based on: | |||
* Type of cells | |||
* Nature of tumor | * Nature of tumor | ||
* | * Location | ||
* Biochemical secretory patterns | * Biochemical secretory patterns | ||
* Genetics | * Genetics | ||
* Mutations and pathogenetic pathways | |||
=== Classification based on nature of tumor | === Classification based on type of cells the tumor is derived from=== | ||
[[Pheochromocytoma|Pheochromocytomas]] and [[Paraganglioma|paragangliomas]] may be classified according to the cells they are derived from: <ref>{{cite book | last = Jameson | first = J | title = Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK | publisher = McGraw-Hill Medical | location = New York | year = 2017 | isbn = 978-1260128857 }} </ref> | |||
*[[Sympathetic nervous system|Sympathetic]]- adrenal medulla or sympathetic trunk | |||
*[[Parasympathetic nervous system|Parasympathetic]]- [[carotid body]], glomus tympanicum, [[Glomus jugulare tumor|glomus jugulare]], [[Glomus tumor|glomus vagale]]. | |||
=== Classification based on nature of tumor === | |||
* [[benign|Benign]] | * [[benign|Benign]] | ||
* [[Malignant]] | *[[Metastatic]]/ [[Malignant]] | ||
[[Malignant]] and [[benign]] [[Tumor|tumors]] share the same [[biochemical]] and [[histological]] characters. The only difference is the ability of the [[malignant]] [[tumor]] to [[metastasize]] to distant [[Tissue (biology)|tissues]] and have high rates of recurrence. | [[Malignant]] and [[benign]] [[Tumor|tumors]] share the same [[biochemical]] and [[histological]] characters. The only difference is the ability of the [[malignant]] [[tumor]] to [[metastasize]] to distant [[Tissue (biology)|tissues]] and have high rates of recurrence. | ||
* According to the WHO 2017 Classification of Tumors of Endocrine Organs, all parangangliomas have metastatic potential and hence the term "malignant" was replaced with "metastatic". <ref name="pmidorcid.org/0000-0003-2771-564X">{{cite journal| author=Smith RJ, Bryant RG| title=Metal substitutions incarbonic anhydrase: a halide ion probe study. | journal=Biochem Biophys Res Commun | year= 1975 | volume= 66 | issue= 4 | pages= 1281-6 | pmid=orcid.org/0000-0003-2771-564X | doi=10.1016/0006-291x(75)90498-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3 }} </ref> | * According to the WHO 2017 Classification of Tumors of Endocrine Organs, all parangangliomas have metastatic potential and hence the term "malignant" was replaced with "metastatic". <ref name="pmidorcid.org/0000-0003-2771-564X">{{cite journal| author=Smith RJ, Bryant RG| title=Metal substitutions incarbonic anhydrase: a halide ion probe study. | journal=Biochem Biophys Res Commun | year= 1975 | volume= 66 | issue= 4 | pages= 1281-6 | pmid=orcid.org/0000-0003-2771-564X | doi=10.1016/0006-291x(75)90498-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3 }} </ref> | ||
* Common sites of metastasis include: | * Common sites of metastasis include: | ||
** [[Lung]] | ** [[Lung]] | ||
| Line 33: | Line 32: | ||
** [[Liver]] | ** [[Liver]] | ||
===Biochemical secretory pattern=== | === Classification based on location=== | ||
* 95% of pheochromocytomas are found in the [[abdomen]] | |||
* '''Intra-[[Adrenal gland|adrenal]]'''- 85-90% | |||
* '''Extra-[[Adrenal gland|adrenal]] ([[Paraganglioma|paragangliomas]])'''- 10-15% are prevertebral and paravertebral sympathetic ganglia of the chest, abdomen, and pelvis. | |||
** The tumors in the abdomen most commonly arise from the organ of Zuckerkandl which is a collection of chromaffin tissue around the origin of the inferior mesenteric artery or the bifurcation of aorta. <ref name="pmid11903030">{{cite journal| author=Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P | display-authors=etal| title=Biochemical diagnosis of pheochromocytoma: which test is best? | journal=JAMA | year= 2002 | volume= 287 | issue= 11 | pages= 1427-34 | pmid=11903030 | doi=10.1001/jama.287.11.1427 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11903030 }} </ref> <ref name="pmid16112304">{{cite journal| author=Lenders JW, Eisenhofer G, Mannelli M, Pacak K| title=Phaeochromocytoma. | journal=Lancet | year= 2005 | volume= 366 | issue= 9486 | pages= 665-75 | pmid=16112304 | doi=10.1016/S0140-6736(05)67139-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16112304 }} </ref> | |||
=== Classification based on biochemical secretory pattern=== | |||
Pheochromocytoma and paragangliomas (PPGL) can be classified based on the biochemical secretory pattern: <ref name="pmidorcid.org/0000-0003-2771-564X">{{cite journal| author=Smith RJ, Bryant RG| title=Metal substitutions incarbonic anhydrase: a halide ion probe study. | journal=Biochem Biophys Res Commun | year= 1975 | volume= 66 | issue= 4 | pages= 1281-6 | pmid=orcid.org/0000-0003-2771-564X | doi=10.1016/0006-291x(75)90498-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3 }} </ref> | Pheochromocytoma and paragangliomas (PPGL) can be classified based on the biochemical secretory pattern: <ref name="pmidorcid.org/0000-0003-2771-564X">{{cite journal| author=Smith RJ, Bryant RG| title=Metal substitutions incarbonic anhydrase: a halide ion probe study. | journal=Biochem Biophys Res Commun | year= 1975 | volume= 66 | issue= 4 | pages= 1281-6 | pmid=orcid.org/0000-0003-2771-564X | doi=10.1016/0006-291x(75)90498-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3 }} </ref> | ||
* Noradrenergic phenotype (predominant norepinephrine secreting)- associated with Von Hippel-Lindau syndrome | *[[Noradrenergic]] [[phenotype]] (predominant [[norepinephrine]] secreting)- associated with [[Von Hippel-Lindau disease|Von Hippel-Lindau syndrome]] | ||
* Adrenergic phenotype (predominant epinephrine secreting)- associated with MEN2 or neurofibromatosis type 1 (NF1) | *[[Adrenergic]] [[phenotype]] (predominant [[epinephrine]] secreting)- associated with [[Multiple endocrine neoplasia type 2|MEN2]] or [[neurofibromatosis type 1]] (NF1) | ||
* Dopamine secreting- associated with SDHB, SDHD or SDHC mutations and potentially metastatic tumors. | *[[Dopamine]] secreting- associated with [[SDHB]], [[SDHD]] or [[SDHC]] [[Mutation|mutations]] and potentially [[Metastasis|metastatic]] tumors. | ||
=== | === Classification based on genetics === | ||
==== Familial pheochromocytoma ==== | ==== Familial pheochromocytoma ==== | ||
| Line 59: | Line 65: | ||
* Sporadic tumors may be due to spontaneous mutation, decreased penetrance or [[Genomic imprinting|maternal imprinting]].<ref name="pmid22517557">{{cite journal| author=Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N et al.| title=A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. | journal=Horm Metab Res | year= 2012 | volume= 44 | issue= 5 | pages= 359-66 | pmid=22517557 | doi=10.1055/s-0032-1304594 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517557 }}</ref> | * Sporadic tumors may be due to spontaneous mutation, decreased penetrance or [[Genomic imprinting|maternal imprinting]].<ref name="pmid22517557">{{cite journal| author=Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N et al.| title=A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. | journal=Horm Metab Res | year= 2012 | volume= 44 | issue= 5 | pages= 359-66 | pmid=22517557 | doi=10.1055/s-0032-1304594 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517557 }}</ref> | ||
* 50% of patients had a pathogenic [[mutation]] in ''[[SDHB]]'', ''[[SDHD]]'', or ''[[Von Hippel-Lindau tumor suppressor|VHL.]]''<ref name="pmid230723242">{{cite journal| author=Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV et al.| title=Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. | journal=Clin Endocrinol (Oxf) | year= 2013 | volume= 78 | issue= 6 | pages= 898-906 | pmid=23072324 | doi=10.1111/cen.12074 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23072324 }}</ref> | * 50% of patients had a pathogenic [[mutation]] in ''[[SDHB]]'', ''[[SDHD]]'', or ''[[Von Hippel-Lindau tumor suppressor|VHL.]]''<ref name="pmid230723242">{{cite journal| author=Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV et al.| title=Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. | journal=Clin Endocrinol (Oxf) | year= 2013 | volume= 78 | issue= 6 | pages= 898-906 | pmid=23072324 | doi=10.1111/cen.12074 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23072324 }}</ref> | ||
===Classification based on mutations and pathogenetic pathways=== | |||
Pheochromocytoma and paragangliomas (PPGL) can be classified into the following clusters- <ref>{{cite book | last = Jameson | first = J | title = Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK | publisher = McGraw-Hill Medical | location = New York | year = 2017 | isbn = 978-1260128857 }} </ref> <ref name="pmid15613462">{{cite journal| author=Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM | display-authors=etal| title=Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. | journal=Endocr Relat Cancer | year= 2004 | volume= 11 | issue= 4 | pages= 897-911 | pmid=15613462 | doi=10.1677/erc.1.00838 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15613462 }} </ref> <ref name="pmid28477311">{{cite journal| author=Lam AK| title=Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. | journal=Endocr Pathol | year= 2017 | volume= 28 | issue= 3 | pages= 213-227 | pmid=28477311 | doi=10.1007/s12022-017-9484-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28477311 }} </ref> | |||
* Cluster 1 | |||
**[[Mutation|Mutations]] involving in [[overexpression]] of [[Vascular endothelial growth factor (VEGF) IRES A|vascular endothelial growth factor (VEGF)]] as a result of pseudohypoxia | |||
** Impaired [[DNA]] [[methylation]] leading to increased vascularization | |||
* Cluster 2 | |||
** Activating [[Mutation|mutations]] of [[Wnt signaling pathway|Wnt-signaling pathway]] including Wnt receptor signaling and [[Hedgehog signaling pathway|Hedgehog]] signaling. | |||
** Mutations of [[CSDE1]] (Cold shock domain containing E1) and [[MAML2|MAML3]] (Mastermind like transcriptional coactivator 3) genes7. | |||
* Cluster 3 | |||
** Abnormal activation of [[Kinase|kinase signaling pathways]] like PI3Kinase/[[AKT]], [[RAS]]/RAF/ERK, and [[mTOR]] pathways. | |||
== References == | == References == | ||
Latest revision as of 20:35, 24 July 2020
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma classification On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma classification |
|
Risk calculators and risk factors for Pheochromocytoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytomas and paragangliomas (collectively referred to as PPGLs) are rare tumors that originate from chromaffin cells in the adrenal medulla (pheochromocytoma) or in the extra-adrenal neural ganglia (paraganglioma). These tumors can be either biochemically active (producing a catecholamine like epinephrine, nor-epinephrine and dopamine) or biochemically silent. PPGLs can be either sporadic or genetic, with association to several familial syndromes. PPGLs can also be classified according to their spread into local, regional, or metastatic. The defining characteristic of malignancy in PPGLs is the presence of metastasis.
Classification
Pheochromocytoma and paragangliomas may be classified into several subtypes based on:
- Type of cells
- Nature of tumor
- Location
- Biochemical secretory patterns
- Genetics
- Mutations and pathogenetic pathways
Classification based on type of cells the tumor is derived from
Pheochromocytomas and paragangliomas may be classified according to the cells they are derived from: [1]
- Sympathetic- adrenal medulla or sympathetic trunk
- Parasympathetic- carotid body, glomus tympanicum, glomus jugulare, glomus vagale.
Classification based on nature of tumor
Malignant and benign tumors share the same biochemical and histological characters. The only difference is the ability of the malignant tumor to metastasize to distant tissues and have high rates of recurrence.
- According to the WHO 2017 Classification of Tumors of Endocrine Organs, all parangangliomas have metastatic potential and hence the term "malignant" was replaced with "metastatic". [2]
- Common sites of metastasis include:
Classification based on location
- 95% of pheochromocytomas are found in the abdomen
- Intra-adrenal- 85-90%
- Extra-adrenal (paragangliomas)- 10-15% are prevertebral and paravertebral sympathetic ganglia of the chest, abdomen, and pelvis.
Classification based on biochemical secretory pattern
Pheochromocytoma and paragangliomas (PPGL) can be classified based on the biochemical secretory pattern: [2]
- Noradrenergic phenotype (predominant norepinephrine secreting)- associated with Von Hippel-Lindau syndrome
- Adrenergic phenotype (predominant epinephrine secreting)- associated with MEN2 or neurofibromatosis type 1 (NF1)
- Dopamine secreting- associated with SDHB, SDHD or SDHC mutations and potentially metastatic tumors.
Classification based on genetics
Familial pheochromocytoma
- Familial pheochromocytoma is associated with several hereditary disorders such as:
- Multiple Endocrine Neoplasia types 2A
- 2B (MEN2) (caused by mutations of the RET gene)
- Von Hippel-Lindau (VHL) disease (caused by mutations of the VHL gene)
- Familial paraganglioma of the neck (cause by mutations of the gene for succinate dehydrogenase subunit D (SDHD))
- Neurofibromatosis type 1 (NF1)
Non-familial pheochromocytoma
- Resulting from sporadic germ-line mutations, which have been documented in about 20% of cases.
- The majority of them are positive for KIT expression. A partial explanation was provided by the finding of activating mutations in another gene encoding an RTK, the platelet-derived growth factor receptor alpha (PDGFRA) gene in some KIT-negative GISTs
Sporadic
- Most catecholamine-secreting tumors are sporadic. Mutations have been identified in most of the sporadic cases.
- Sporadic tumors may be due to spontaneous mutation, decreased penetrance or maternal imprinting.[5]
- 50% of patients had a pathogenic mutation in SDHB, SDHD, or VHL.[6]
Classification based on mutations and pathogenetic pathways
Pheochromocytoma and paragangliomas (PPGL) can be classified into the following clusters- [7] [8] [9]
- Cluster 1
- Mutations involving in overexpression of vascular endothelial growth factor (VEGF) as a result of pseudohypoxia
- Impaired DNA methylation leading to increased vascularization
- Cluster 2
- Activating mutations of Wnt-signaling pathway including Wnt receptor signaling and Hedgehog signaling.
- Mutations of CSDE1 (Cold shock domain containing E1) and MAML3 (Mastermind like transcriptional coactivator 3) genes7.
- Cluster 3
- Abnormal activation of kinase signaling pathways like PI3Kinase/AKT, RAS/RAF/ERK, and mTOR pathways.
References
- ↑ Jameson, J (2017). Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK. New York: McGraw-Hill Medical. ISBN 978-1260128857.
- ↑ 2.0 2.1 Smith RJ, Bryant RG (1975). "Metal substitutions incarbonic anhydrase: a halide ion probe study". Biochem Biophys Res Commun. 66 (4): 1281–6. doi:10.1016/0006-291x(75)90498-2. PMID orcid.org/0000-0003-2771-564X Check
|pmid=value (help). - ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. doi:10.1001/jama.287.11.1427. PMID 11903030.
- ↑ Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005). "Phaeochromocytoma". Lancet. 366 (9486): 665–75. doi:10.1016/S0140-6736(05)67139-5. PMID 16112304.
- ↑ Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N; et al. (2012). "A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma". Horm Metab Res. 44 (5): 359–66. doi:10.1055/s-0032-1304594. PMID 22517557.
- ↑ Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV; et al. (2013). "Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma". Clin Endocrinol (Oxf). 78 (6): 898–906. doi:10.1111/cen.12074. PMID 23072324.
- ↑ Jameson, J (2017). Harrison's Principles of Internal Medicine 19th Edition and Harrison's Manual of Medicine 19th Edition VAL PAK. New York: McGraw-Hill Medical. ISBN 978-1260128857.
- ↑ Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM; et al. (2004). "Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome". Endocr Relat Cancer. 11 (4): 897–911. doi:10.1677/erc.1.00838. PMID 15613462.
- ↑ Lam AK (2017). "Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours". Endocr Pathol. 28 (3): 213–227. doi:10.1007/s12022-017-9484-5. PMID 28477311.